| Factor Information | |
|---|---|
| Data ID | 544 |
| Factor | Hemoglobin |
| Description | Of the total anemic CHD patients, 21 of 49 (43%) were microcytic (mean corpuscular volume <84 fL) and 46 of 49 (94%) had a mean corpuscular volume under 95 fL |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | hemoglobin and ferritin levels in the whole series of CHD patients, and in CHD patients with anemia, depending on whether they had or did not have associated microcytosis. |
| p Value | <0.001 |
| Conclusion | The incidence of anemia in CHD patients is similar to that of the normal population and iron deficiency anemia accounts for most of the cases. There were no significant differences in mortality between CHD patients with and without anemia. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 468 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | ASD/VSD/AVSD/PS/AOS/Bc/CoA/D-TGA/ccTGA/TOF/EA/other |
| Reference | |
|---|---|
| PMID | 29432304 |
| Year | 2018 |
| Title | Anemia in Adolescents and Young Adult Patients With Congenital Heart Disease. |
| Sample | ||
|---|---|---|
| Population | Adolescents and Young Adult | |
| Source | demographic, clinical, and analytic parameters. | |
| Region | Las Palmas de Gran Canaria, Spain | |
| Method | Binary Logistic Regression Analyses | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | Aspirin; Oral anticoagulation; Betablockers; ACE ( angiotensin-converting enzyme) inhibitors/ARBs(angiotensin receptor blockers); Diuretics | |
| Group | Microcytic(Treatment) | Nonmicrocytic(Control) |
| Number | 91 | 453 |
| Age | N/A | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 13.5(12.6-14.9) mg/dL | 14.5(13.5-15) mg/dL |
